Evidence map›Paper›PMID 34130040›Full record

ReviewCurrent opinion in virology2021

The impact of high-resolution structural data on stemming the COVID-19 pandemic.

Robert M Cox, Richard K Plemper

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Robert M CoxInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. Electronic address: rcox@gsu.edu.
Richard K PlemperInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Georgia State University · US

Funding

Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza VirusesR01AI141222 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2019 to 2023
$5.0M
NIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI141222
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has had a catastrophic impact on human health and the world economy. The response of the scientific community was unparalleled, and a combined global effort has resulted in the creation of vaccines in a shorter time frame than previously unimaginable. Reflecting this concerted effort, the structural analysis of the etiological agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has progressed with an unprecedented pace. Since the onset of the pandemic, over 1000 high-resolution structures of a broad range of SARS-CoV-2 proteins have been solved and made publicly available. These structures have aided in the identification of numerous potential druggable targets and have contributed to the design of different vaccine candidates. This opinion article will discuss the impact of high-resolution structures in understanding SARS-CoV-2 biology and explore their role in the development of vaccines and antivirals.

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesCoronavirus RNA-Dependent RNA PolymeraseCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesHumansSARS-CoV-2Spike Glycoprotein, Coronavirus3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCoronavirus RNA-Dependent RNA PolymeraseCOVID-19 VaccinesNSP12 protein, SARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID34130040
PMCPMC8173484
OpenAlexW3166059846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.